Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Hidekazu Ochiai"'
1
Akademický článek
Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
Autor: Yuji Kumagai, Tomoko Hasunuma, Soichi Sakai, Hidekazu Ochiai, Yoshishige Samukawa
Publikováno v: PLoS ONE, Vol 10, Iss 10, p e0139873 (2015)
Luseogliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor. To evaluate the cardiac safety of luseogliflozin, a thorough QT/QTc study was conducted in healthy Japanese subjects. The effects of moxifloxacin on QT prolongation in J
Externí odkaz: https://doaj.org/article/092ec9bd16d148e1a35416e958816719
Zobrazit plný text záznamu
2
Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials
Autor: Hidekazu Ochiai, Yutaka Seino, Shi Chen, Motoaki Sano, Hisae Imazeki
Publikováno v: Journal of Diabetes Investigation
We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with highe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eebdc4693f60b5c95eee3d9cfb01983
https://doi.org/10.1111/jdi.12726
Zobrazit plný text záznamu
3
Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study
Autor: Soichi Sakai, Yuji Kumagai, Naohiko Ueda, Michio Sata, Yoshishige Samukawa, Toshifumi Ito, Kenichi Furihata, Hidekazu Ochiai
Publikováno v: Clinical Pharmacology in Drug Development. 6:439-447
This open-label, parallel-group study evaluated the effect of mild and moderate hepatic impairment on the pharmacokinetics of a single dose of luseogliflozin in Japanese subjects. Thirteen subjects with hepatic impairment (mild, n = 8; moderate, n =
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99540c63fcc17a285795dae482d72dc2
https://doi.org/10.1002/cpdd.364
Zobrazit plný text záznamu
4
Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, singl
Autor: Daisuke Yabe, Soichi Sakai, Atsushi Fukatsu, Yutaka Seino, Hidekazu Ochiai, Takashi Sasaki, Hisae Imazeki
Publikováno v: Journal of Diabetes Investigation
Aims/Introduction The aim of the present study was to evaluate the safety and efficacy of luseogliflozin added to liraglutide monotherapy in Japanese individuals with type 2 diabetes. Materials and Methods This 52-week, multicenter, open-label, singl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f2e18a6adbedb62bef0fc5c1919d4a
https://doi.org/10.1111/jdi.12694
Zobrazit plný text záznamu
5
Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period
Autor: Yutaka Seino, Hisae Imazeki, Takashi Sasaki, Soichi Sakai, Atsushi Fukatsu, Hidekazu Ochiai
To evaluate the efficacy and safety of luseogliflozin in Japanese patients with type 2 diabetes (T2D) inadequately controlled with insulin monotherapy.This 52-week multicenter study entailed a 16-week, double-blind period followed by a 36-week, open-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::708be948d6191a78c084d41504ecd482
Zobrazit plný text záznamu
6
Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
Autor: Soichi Sakai, Yuji Kumagai, Yoshishige Samukawa, Tomoko Hasunuma, Hidekazu Ochiai
Publikováno v: PLoS ONE, Vol 10, Iss 10, p e0139873 (2015)
PLoS ONE
Luseogliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor. To evaluate the cardiac safety of luseogliflozin, a thorough QT/QTc study was conducted in healthy Japanese subjects. The effects of moxifloxacin on QT prolongation in J
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03d073d2834be0ff84e2cd4df4d8ba31
http://europepmc.org/articles/PMC4596473?pdf=render
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje